Silymarin for HCV infection | Zendy

Stephen J. Polyak | Zendy; Nicholas H. Oberlies | Zendy; Ève-Isabelle Pécheur | Zendy; Harel Dahari | Zendy; Peter Ferenci | Zendy; JeanMichel Pawlotsky | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Silymarin for HCV infection

Author(s) -

Stephen J. Polyak,

Nicholas H. Oberlies,

Ève-Isabelle Pécheur,

Harel Dahari,

Peter Ferenci,

JeanMichel Pawlotsky

Publication year - 2012

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp2402

Subject(s) - silibinin , milk thistle , hepatoprotection , context (archaeology) , medicine , pharmacology , traditional medicine , biology , immunology , glutathione , paleontology , biochemistry , enzyme

Silymarin, an extract of milk thistle seeds, and silymarin-derived compounds have been considered hepatoprotective since the plant was first described in ancient times. Hepatoprotection is defined as several non-mutually exclusive biological activities including antiviral, antioxidant, anti-inflammatory and immunomodulatory functions. Despite clear evidence for silymarin-induced hepatoprotection in cell culture and animal models, evidence for beneficial effects in humans has been equivocal. This review will summarize the current state of knowledge on silymarin in the context of HCV infection. The information was collated from a recent workshop on silibinin in Germany.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research